As with glycemic control and microvascular complications, insulin therapy is generally reserved for patients with more complicated T2DM, and therefore its independent association with fracture risk is particularly difficult to determine in the absence of a prospective randomized controlled trial (RCT). The gene discussed is INS; the disease is type 2 diabetes mellitus.